Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes

Diabetes Care. 2006 May;29(5):1180. doi: 10.2337/diacare.2951180.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cyclohexanes / therapeutic use*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / prevention & control*
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / metabolism*
  • Insulin Secretion
  • Nateglinide
  • Phenylalanine / analogs & derivatives*
  • Phenylalanine / therapeutic use
  • Postprandial Period
  • Triglycerides / blood

Substances

  • Cyclohexanes
  • Hypoglycemic Agents
  • Insulin
  • Triglycerides
  • Nateglinide
  • Phenylalanine